Lexington biotech gets second FDA rejection this year

The U.S. Food and Drug Administration has rejected a drug made by a Lexington biotech just a few months after it rejected another drug by the same company.

Previous Novavax’s Covid vaccine wins critical World Health Organization green light
Next KU Health joins KC Current as team's official medical provider